CorMedix (NASDAQ: CRMD) reported Q2 EPS of $0.29, $0.06 better than the analyst estimate of $0.23. Revenue for the quarter came in at $101.93 million versus the consensus estimate of $95.62 million.

GUIDANCE:

CorMedix sees FY2026 revenue of $325-345 million, versus the consensus of $334.6 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.